Search

Your search keyword '"Robert Gut"' showing total 14 results
Start Over "Robert Gut" Journal globenewswire
14 results on '"Robert Gut"'

1. Versartis Announces Expansion of Executive Leadership Team with Addition of Dr. Robert Gut as the Head of Global Clinical, Medical and Regulatory Affairs

Subjects
Somatotropin, Banking, finance and accounting industries, Business, Norditropin (Medication)
Abstract

MENLO PARK, Calif., Sep 05, 2017 (GLOBE NEWSWIRE via COMTEX) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of recombinant human growth [...]

Published
2017

3. uniQure Announces Achievement of Target Patient Dosing in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Hemophilia

Subjects
United States. Food and Drug Administration, Hemophilia -- Care and treatment, Factor IX -- Product development, Hemophilia B -- Care and treatment, Genes, Time, Clinical trials, Patent law, Banking, finance and accounting industries, Business
Abstract

LEXINGTON, Mar 26, 2020 (GLOBE NEWSWIRE via COMTEX) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced [...]

Published
2020

4. uniQure Announces One-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia

Subjects
Hemophilia -- Care and treatment -- Health aspects, Factor IX -- Product development -- Health aspects, Immunotherapy -- Health aspects, Genes, Hemophilia B, Banking, finance and accounting industries, Business
Abstract

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec 08, 2019 (GLOBE NEWSWIRE via COMTEX) -- ~ Sustained FIX Activity at Therapeutic Levels Up to 50% of Normal at One Year After [...]

Published
2019

5. uniQure Announces Publication of Positive Interim Data from Phase IIb Clinical Trial of Etranacogene Dezaparvovec

Subjects
Clinical trials, Hemophilia, Gene therapy, Factor IX -- Product development, Genes, Hemophilia B, Banking, finance and accounting industries, Business
Abstract

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct 31, 2019 (GLOBE NEWSWIRE via COMTEX) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe [...]

Published
2019

6. uniQure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia

Subjects
Hemophilia -- Care and treatment, Factor IX, Medical research, Hemophilia B -- Care and treatment, Genes, Patent law, Banking, finance and accounting industries, Business
Abstract

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sep 04, 2019 (GLOBE NEWSWIRE via COMTEX) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe [...]

Published
2019

9. uniQure Announces First Patient Treated in HOPE-B Pivotal Trial of AMT-061 in Patients with Hemophilia

Subjects
Factor IX -- Intellectual property, Hemophilia B -- Care and treatment, Hemophilia -- Care and treatment, Patents, Patent law, Genes, Clinical trials, Banking, finance and accounting industries, Business
Abstract

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb 04, 2019 (GLOBE NEWSWIRE via COMTEX) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe [...]

Published
2019

10. uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia

Subjects
Hemophilia -- Care and treatment, Factor IX, Medical research, Hemophilia B -- Care and treatment, Banking, finance and accounting industries, Business
Abstract

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Aug 23, 2018 (GLOBE NEWSWIRE via COMTEX) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet [...]

Published
2018

11. uniQure Announces Second Quarter 2018 Financial Results and Highlights Company Progress

Subjects
United States. Food and Drug Administration -- Officials and employees, Banking, finance and accounting industries, Business
Abstract

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Aug 08, 2018 (GLOBE NEWSWIRE via COMTEX) -- ~ Patient Enrollment Underway in Global Phase III HOPE-B Pivotal Study of AMT-061 ~ First Patient [...]

Published
2018

12. uniQure Announces New Appointments to its Board of Directors

Subjects
Banking, finance and accounting industries, Business
Abstract

LEXINGTON, Jun 13, 2018 (GLOBE NEWSWIRE via COMTEX) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment [...]

Published
2018

13. uniQure Announces First Quarter 2018 Financial Results and Highlights Company Progress

Subjects
United States. Food and Drug Administration -- Officials and employees, Company earnings/profit, Banking, finance and accounting industries, Business
Abstract

LEXINGTON, Apr 30, 2018 (GLOBE NEWSWIRE via COMTEX) -- ~ Patient enrollment expected to begin ahead of schedule in dose-confirmation study for AMT-061 and pivotal study on track to commence [...]

Published
2018

14. Radius Health to Present First Health Economics Data on TYMLOS(TM) (abaloparatide) Injection at the Academy of Managed Care Pharmacy Nexus 2017

Subjects
Osteoporosis -- Health aspects, Health care industry -- Health aspects, Managed care plans (Medical care) -- Health aspects, Pharmacy -- Health aspects, Health care industry, Company business management, Banking, finance and accounting industries, Business, Tymlos (Medication) -- Health aspects
Abstract

WALTHAM, Mass., Oct 13, 2017 (GLOBE NEWSWIRE via COMTEX) -- Five posters will cover new data on the need for osteoporosis awareness as well as cost-effectiveness data on treatment with [...]

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results